Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.84 |
| ▸ | PDE2A | O00408 | 4/20 | 0.81 |
| ▸ | PDE8A | O60658 | 4/20 | 0.81 |
| ▸ | PDE5A | O76074 | 4/20 | 0.81 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.81 |
| ▸ | PDE11A | Q9HCR9 | 4/20 | 0.81 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.81 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.81 |
| ▸ | PDE9A | O76083 | 3/20 | 0.81 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.81 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.81 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21182694 | 1.00 | PDE4A (0.84) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL19217069 | 0.98 | PDE4A (0.81) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL18380631 | 0.92 | PDE4A (0.85) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL18771113 | 0.91 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL18211963 | 0.91 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL29415040 | 0.91 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL16324627 | 0.91 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL10201342 | 0.91 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL23679709 | 0.90 | PDE4A (0.81) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL20341393 | 0.90 | PDE4A (0.97) | PDE4APDE2APDE8APDE5APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177627-B1 | IMIDAZO[1,2-A]-PYRAZOLO[4,3-E]-PYRIMIDIN-4-ONE DERIVATIVES WITH PDE1 INHIBITING ACTIVITY | INTRA CELLULAR THERAPIES INC (US) | 2019-07-24 | — | — | EP | claimed |
| EP-3177627-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2017-06-14 | — | — | EP | claimed |
| WO-2016022893-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-11 | — | — | WO | claimed |
| US-20230355625-A1 | METHODS OF TREATMENT | INTRA-CELLULAR THERAPIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355625-A1 | METHODS OF TREATMENT | INTRA-CELLULAR THERAPIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11759465-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759465-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220280517-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20210369715-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210338679-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20200289519-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2020-09-17 | — | — | US | disclosed |
| EP-3177627-B1 | IMIDAZO[1,2-A]-PYRAZOLO[4,3-E]-PYRIMIDIN-4-ONE DERIVATIVES WITH PDE1 INHIBITING ACTIVITY | INTRA CELLULAR THERAPIES INC (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20170226117-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226117-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-3177627-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016022893-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022893-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226117-A1 | ORGANIC COMPOUNDS | PRKG1, PDE2A, PDE3B | PDE4A 8/4885PDE2A 2/4885PDE8A 323/4885 |
| US-20230355625-A1 | METHODS OF TREATMENT | PDE1A, PDE1B, PDE7A | PDE4A 4/4885PDE2A 10/4885PDE8A 16/4885 |
| US-20210338679-A1 | NOVEL USES | PDE2A, PDE7A, PDE4A | PDE4A 3/4885PDE2A 1/4885PDE8A 18/4885 |
| US-20200289519-A1 | NOVEL USES | ADORA2A, ATP2A1, ADORA2B | PDE4A 11/4885PDE2A 4/4885PDE8A 34/4885 |
| US-20230338385-A1 | NOVEL USES | ADORA2A, ATP2A1, ADORA2B | PDE4A 11/4885PDE2A 4/4885PDE8A 34/4885 |
| US-20220280517-A1 | ORGANIC COMPOUNDS | PDE3A, PDE3B, PDE2A | PDE4A 11/4885PDE2A 3/4885PDE8A 161/4885 |
| US-20210369715-A1 | NOVEL USES | PDE2A, PDE7A, PDE4A | PDE4A 3/4885PDE2A 1/4885PDE8A 18/4885 |
| US-11759465-B2 | Uses | ADORA2A, ADORA2B, ADORA1 | PDE4A 12/4885PDE2A 4/4885PDE8A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.